Loading…
Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide
We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. 101 mCRPC patients were included. PNI was calculated using formula 10 x serum a...
Saved in:
| Published in: | Actas urológicas españolas (English ed.) 2022-06, Vol.46 (5), p.301-309 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | eng ; spa |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c2074-8fc42a59cdc946f96f529840216b23a230fac70b3d1c1494c5b0586105eeae7a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c2074-8fc42a59cdc946f96f529840216b23a230fac70b3d1c1494c5b0586105eeae7a3 |
| container_end_page | 309 |
| container_issue | 5 |
| container_start_page | 301 |
| container_title | Actas urológicas españolas (English ed.) |
| container_volume | 46 |
| creator | Küçükarda, A. Gökyer, A. Gökmen, İ. Özcan, E. Hacıoğlu, M.B. Erdoğan, B. Uzunoğlu, S. Çiçin, İ. |
| description | We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
101 mCRPC patients were included. PNI was calculated using formula 10 x serum albumin value (gr/dL) + 0.005 × total lymphocyte count (per mm3). ROC analysis was used for determining prognostic PNI value.
The statistically significant cut-off value for PNI was 46.62. Initial PSA response and PSA kinetics (early PSA response and 30 %–50%–90% PSA response at any time) were much better in PNI > 46.62 group than the PNI ≤ 46.62 group (p 46.62 was an independent predictor of PSA-PFS (HR: 0.42, p |
| doi_str_mv | 10.1016/j.acuroe.2021.12.005 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2637318186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S217357862100158X</els_id><sourcerecordid>2637318186</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2074-8fc42a59cdc946f96f529840216b23a230fac70b3d1c1494c5b0586105eeae7a3</originalsourceid><addsrcrecordid>eNp9Uctu1TAQjRCIVqV_gJCXLEjwI3aSDRKqeEmVYAFry7Enra9u7Ivt3AL_yf8waS6PFZZsjzznnJnxqaqnjDaMMvVy1xi7pAgNp5w1jDeUygfVOWedqGXXq4f_xGfVZc47iku1Qg7icXUmJJdK8Pa8-vkpxZsQc_GWhKUkX3wMZk98cPCN-ExMuI8PgEco5PAXPhlbYiIT7pLAlHnNJ8iHGDK8IHlJR39EKRMccWm5IfY2egsoR2YoJhezqlgMklmr1sj1-LpVWdOA2WDhpA-O3PlyS8zokQApBiDGwj0Oe4Dww-yXYmbv4En1aDL7DJen-6L68vbN56v39fXHdx-uXl_XltOurfvJttzIwTo7tGoa1CT50Lf4pWrkwnBBccaOjsIxy9qhtXKksleMSgADnREX1fNNFxv-ukAuevbZwn5vAsQla65EJ1jPeoXQdoNanC0nmPQh-dmk75pRvXqqd3rzVK-easY1eoq0Z6cKyziD-0P67SACXm0AwDmPHpLO1gP-mvMJbNEu-v9X-AVW4ruC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637318186</pqid></control><display><type>article</type><title>Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Küçükarda, A. ; Gökyer, A. ; Gökmen, İ. ; Özcan, E. ; Hacıoğlu, M.B. ; Erdoğan, B. ; Uzunoğlu, S. ; Çiçin, İ.</creator><creatorcontrib>Küçükarda, A. ; Gökyer, A. ; Gökmen, İ. ; Özcan, E. ; Hacıoğlu, M.B. ; Erdoğan, B. ; Uzunoğlu, S. ; Çiçin, İ.</creatorcontrib><description><![CDATA[We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
101 mCRPC patients were included. PNI was calculated using formula 10 x serum albumin value (gr/dL) + 0.005 × total lymphocyte count (per mm3). ROC analysis was used for determining prognostic PNI value.
The statistically significant cut-off value for PNI was 46.62. Initial PSA response and PSA kinetics (early PSA response and 30 %–50%–90% PSA response at any time) were much better in PNI > 46.62 group than the PNI ≤ 46.62 group (p < 0.01). In multivariate analysis, baseline PNI level >46.62 was an independent predictor of PSA-PFS (HR: 0.42, p < 0.01), radiologic PFS (HR: 0.53, p < 0.01), and OS (HR: 0.42, p < 0.01). In the PNI ≤ 46.62 group, median OS was 7.4 months (95% CI: 4.1–10.7) for the abiraterone acetate subgroup vs. 17.6 months (95% CI: 10.1–25.1) for enzalutamide subgroups (p < 0.01).
PNI is a useful, independent prognostic marker for mCRPC patients treated with either abiraterone acetate or enzalutamide. Using pre-treatment PNI may help clinicians in the prediction of survival and decision making based on abiraterone acetate or enzalutamide.
El objetivo del presente fue identificar el valor pronóstico del índice nutricional pronóstico (INP) basal en pacientes con cáncer de próstata resistente a la castración metastásico (CPRCm) tratados con acetato de abiraterona o enzalutamida.
Se incluyeron 101 pacientes de CPRCm. El INP se calculó mediante la fórmula 10 x valor de albúmina sérica (gr/dL) + 0,005 × recuento total de linfocitos (mm3). Se utilizó el análisis ROC para determinar el valor pronóstico del INP.
El valor de corte estadísticamente significativo para el INP fue 46,62. La respuesta inicial del PSA y la cinética del PSA (respuesta precoz por PSA y respuesta por PSA del 30%–50%–90% en cualquier momento) fueron mucho mejores en el grupo INP > 46,62 que en el grupo INP ≤ 46,62 (p < 0,01). En el análisis multivariante, el INP basal >46,62 fue un predictor independiente de la SLP por PSA (HR: 0,42, p < 0,01), la SLP radiológica (HR: 0,53, p < 0,01) y la SG (HR: 0,42, p < 0,01). En el grupo de INP ≤ 46,62, la mediana de la SG fue de 7,4 meses (IC 95%: 4,1–10,7) para el subgrupo de acetato de abiraterona, frente a 17,6 meses (IC 95%: 10,1–25,1) para los subgrupos de enzalutamida (p < 0,01).
El INP es un marcador pronóstico útil e independiente para los pacientes con CPRCm tratados con acetato de abiraterona o enzalutamida. El uso del INP previo al tratamiento puede ayudar a los médicos en la predicción de la supervivencia y en la elección de acetato de abiraterona o enzalutamida.]]></description><identifier>ISSN: 2173-5786</identifier><identifier>EISSN: 2173-5786</identifier><identifier>DOI: 10.1016/j.acuroe.2021.12.005</identifier><identifier>PMID: 35256324</identifier><language>eng ; spa</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Abiraterone acetate ; Acetato de abiraterona ; Castration-resistant prostate cancer ; Cáncer de próstata resistente a la castración ; Enzalutamida ; Enzalutamide ; Prognostic nutritional index ; Índice nutricional pronóstico</subject><ispartof>Actas urológicas españolas (English ed.), 2022-06, Vol.46 (5), p.301-309</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier España, S.L.U.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2074-8fc42a59cdc946f96f529840216b23a230fac70b3d1c1494c5b0586105eeae7a3</citedby><cites>FETCH-LOGICAL-c2074-8fc42a59cdc946f96f529840216b23a230fac70b3d1c1494c5b0586105eeae7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35256324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Küçükarda, A.</creatorcontrib><creatorcontrib>Gökyer, A.</creatorcontrib><creatorcontrib>Gökmen, İ.</creatorcontrib><creatorcontrib>Özcan, E.</creatorcontrib><creatorcontrib>Hacıoğlu, M.B.</creatorcontrib><creatorcontrib>Erdoğan, B.</creatorcontrib><creatorcontrib>Uzunoğlu, S.</creatorcontrib><creatorcontrib>Çiçin, İ.</creatorcontrib><title>Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide</title><title>Actas urológicas españolas (English ed.)</title><addtitle>Actas Urol Esp (Engl Ed)</addtitle><description><![CDATA[We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
101 mCRPC patients were included. PNI was calculated using formula 10 x serum albumin value (gr/dL) + 0.005 × total lymphocyte count (per mm3). ROC analysis was used for determining prognostic PNI value.
The statistically significant cut-off value for PNI was 46.62. Initial PSA response and PSA kinetics (early PSA response and 30 %–50%–90% PSA response at any time) were much better in PNI > 46.62 group than the PNI ≤ 46.62 group (p < 0.01). In multivariate analysis, baseline PNI level >46.62 was an independent predictor of PSA-PFS (HR: 0.42, p < 0.01), radiologic PFS (HR: 0.53, p < 0.01), and OS (HR: 0.42, p < 0.01). In the PNI ≤ 46.62 group, median OS was 7.4 months (95% CI: 4.1–10.7) for the abiraterone acetate subgroup vs. 17.6 months (95% CI: 10.1–25.1) for enzalutamide subgroups (p < 0.01).
PNI is a useful, independent prognostic marker for mCRPC patients treated with either abiraterone acetate or enzalutamide. Using pre-treatment PNI may help clinicians in the prediction of survival and decision making based on abiraterone acetate or enzalutamide.
El objetivo del presente fue identificar el valor pronóstico del índice nutricional pronóstico (INP) basal en pacientes con cáncer de próstata resistente a la castración metastásico (CPRCm) tratados con acetato de abiraterona o enzalutamida.
Se incluyeron 101 pacientes de CPRCm. El INP se calculó mediante la fórmula 10 x valor de albúmina sérica (gr/dL) + 0,005 × recuento total de linfocitos (mm3). Se utilizó el análisis ROC para determinar el valor pronóstico del INP.
El valor de corte estadísticamente significativo para el INP fue 46,62. La respuesta inicial del PSA y la cinética del PSA (respuesta precoz por PSA y respuesta por PSA del 30%–50%–90% en cualquier momento) fueron mucho mejores en el grupo INP > 46,62 que en el grupo INP ≤ 46,62 (p < 0,01). En el análisis multivariante, el INP basal >46,62 fue un predictor independiente de la SLP por PSA (HR: 0,42, p < 0,01), la SLP radiológica (HR: 0,53, p < 0,01) y la SG (HR: 0,42, p < 0,01). En el grupo de INP ≤ 46,62, la mediana de la SG fue de 7,4 meses (IC 95%: 4,1–10,7) para el subgrupo de acetato de abiraterona, frente a 17,6 meses (IC 95%: 10,1–25,1) para los subgrupos de enzalutamida (p < 0,01).
El INP es un marcador pronóstico útil e independiente para los pacientes con CPRCm tratados con acetato de abiraterona o enzalutamida. El uso del INP previo al tratamiento puede ayudar a los médicos en la predicción de la supervivencia y en la elección de acetato de abiraterona o enzalutamida.]]></description><subject>Abiraterone acetate</subject><subject>Acetato de abiraterona</subject><subject>Castration-resistant prostate cancer</subject><subject>Cáncer de próstata resistente a la castración</subject><subject>Enzalutamida</subject><subject>Enzalutamide</subject><subject>Prognostic nutritional index</subject><subject>Índice nutricional pronóstico</subject><issn>2173-5786</issn><issn>2173-5786</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9Uctu1TAQjRCIVqV_gJCXLEjwI3aSDRKqeEmVYAFry7Enra9u7Ivt3AL_yf8waS6PFZZsjzznnJnxqaqnjDaMMvVy1xi7pAgNp5w1jDeUygfVOWedqGXXq4f_xGfVZc47iku1Qg7icXUmJJdK8Pa8-vkpxZsQc_GWhKUkX3wMZk98cPCN-ExMuI8PgEco5PAXPhlbYiIT7pLAlHnNJ8iHGDK8IHlJR39EKRMccWm5IfY2egsoR2YoJhezqlgMklmr1sj1-LpVWdOA2WDhpA-O3PlyS8zokQApBiDGwj0Oe4Dww-yXYmbv4En1aDL7DJen-6L68vbN56v39fXHdx-uXl_XltOurfvJttzIwTo7tGoa1CT50Lf4pWrkwnBBccaOjsIxy9qhtXKksleMSgADnREX1fNNFxv-ukAuevbZwn5vAsQla65EJ1jPeoXQdoNanC0nmPQh-dmk75pRvXqqd3rzVK-easY1eoq0Z6cKyziD-0P67SACXm0AwDmPHpLO1gP-mvMJbNEu-v9X-AVW4ruC</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Küçükarda, A.</creator><creator>Gökyer, A.</creator><creator>Gökmen, İ.</creator><creator>Özcan, E.</creator><creator>Hacıoğlu, M.B.</creator><creator>Erdoğan, B.</creator><creator>Uzunoğlu, S.</creator><creator>Çiçin, İ.</creator><general>Elsevier España, S.L.U</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202206</creationdate><title>Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide</title><author>Küçükarda, A. ; Gökyer, A. ; Gökmen, İ. ; Özcan, E. ; Hacıoğlu, M.B. ; Erdoğan, B. ; Uzunoğlu, S. ; Çiçin, İ.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2074-8fc42a59cdc946f96f529840216b23a230fac70b3d1c1494c5b0586105eeae7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2022</creationdate><topic>Abiraterone acetate</topic><topic>Acetato de abiraterona</topic><topic>Castration-resistant prostate cancer</topic><topic>Cáncer de próstata resistente a la castración</topic><topic>Enzalutamida</topic><topic>Enzalutamide</topic><topic>Prognostic nutritional index</topic><topic>Índice nutricional pronóstico</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Küçükarda, A.</creatorcontrib><creatorcontrib>Gökyer, A.</creatorcontrib><creatorcontrib>Gökmen, İ.</creatorcontrib><creatorcontrib>Özcan, E.</creatorcontrib><creatorcontrib>Hacıoğlu, M.B.</creatorcontrib><creatorcontrib>Erdoğan, B.</creatorcontrib><creatorcontrib>Uzunoğlu, S.</creatorcontrib><creatorcontrib>Çiçin, İ.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Actas urológicas españolas (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Küçükarda, A.</au><au>Gökyer, A.</au><au>Gökmen, İ.</au><au>Özcan, E.</au><au>Hacıoğlu, M.B.</au><au>Erdoğan, B.</au><au>Uzunoğlu, S.</au><au>Çiçin, İ.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide</atitle><jtitle>Actas urológicas españolas (English ed.)</jtitle><addtitle>Actas Urol Esp (Engl Ed)</addtitle><date>2022-06</date><risdate>2022</risdate><volume>46</volume><issue>5</issue><spage>301</spage><epage>309</epage><pages>301-309</pages><issn>2173-5786</issn><eissn>2173-5786</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract><![CDATA[We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
101 mCRPC patients were included. PNI was calculated using formula 10 x serum albumin value (gr/dL) + 0.005 × total lymphocyte count (per mm3). ROC analysis was used for determining prognostic PNI value.
The statistically significant cut-off value for PNI was 46.62. Initial PSA response and PSA kinetics (early PSA response and 30 %–50%–90% PSA response at any time) were much better in PNI > 46.62 group than the PNI ≤ 46.62 group (p < 0.01). In multivariate analysis, baseline PNI level >46.62 was an independent predictor of PSA-PFS (HR: 0.42, p < 0.01), radiologic PFS (HR: 0.53, p < 0.01), and OS (HR: 0.42, p < 0.01). In the PNI ≤ 46.62 group, median OS was 7.4 months (95% CI: 4.1–10.7) for the abiraterone acetate subgroup vs. 17.6 months (95% CI: 10.1–25.1) for enzalutamide subgroups (p < 0.01).
PNI is a useful, independent prognostic marker for mCRPC patients treated with either abiraterone acetate or enzalutamide. Using pre-treatment PNI may help clinicians in the prediction of survival and decision making based on abiraterone acetate or enzalutamide.
El objetivo del presente fue identificar el valor pronóstico del índice nutricional pronóstico (INP) basal en pacientes con cáncer de próstata resistente a la castración metastásico (CPRCm) tratados con acetato de abiraterona o enzalutamida.
Se incluyeron 101 pacientes de CPRCm. El INP se calculó mediante la fórmula 10 x valor de albúmina sérica (gr/dL) + 0,005 × recuento total de linfocitos (mm3). Se utilizó el análisis ROC para determinar el valor pronóstico del INP.
El valor de corte estadísticamente significativo para el INP fue 46,62. La respuesta inicial del PSA y la cinética del PSA (respuesta precoz por PSA y respuesta por PSA del 30%–50%–90% en cualquier momento) fueron mucho mejores en el grupo INP > 46,62 que en el grupo INP ≤ 46,62 (p < 0,01). En el análisis multivariante, el INP basal >46,62 fue un predictor independiente de la SLP por PSA (HR: 0,42, p < 0,01), la SLP radiológica (HR: 0,53, p < 0,01) y la SG (HR: 0,42, p < 0,01). En el grupo de INP ≤ 46,62, la mediana de la SG fue de 7,4 meses (IC 95%: 4,1–10,7) para el subgrupo de acetato de abiraterona, frente a 17,6 meses (IC 95%: 10,1–25,1) para los subgrupos de enzalutamida (p < 0,01).
El INP es un marcador pronóstico útil e independiente para los pacientes con CPRCm tratados con acetato de abiraterona o enzalutamida. El uso del INP previo al tratamiento puede ayudar a los médicos en la predicción de la supervivencia y en la elección de acetato de abiraterona o enzalutamida.]]></abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>35256324</pmid><doi>10.1016/j.acuroe.2021.12.005</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2173-5786 |
| ispartof | Actas urológicas españolas (English ed.), 2022-06, Vol.46 (5), p.301-309 |
| issn | 2173-5786 2173-5786 |
| language | eng ; spa |
| recordid | cdi_proquest_miscellaneous_2637318186 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Abiraterone acetate Acetato de abiraterona Castration-resistant prostate cancer Cáncer de próstata resistente a la castración Enzalutamida Enzalutamide Prognostic nutritional index Índice nutricional pronóstico |
| title | Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T04%3A49%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20nutritional%20index%20is%20an%20independent%20prognostic%20factor%20for%20treatment%20response,%20survival%20and%20drug%20choice%20in%20metastatic%20castration-resistant%20prostate%20cancer%20treated%20with%20abiraterone%20acetate%20or%20enzalutamide&rft.jtitle=Actas%20urol%C3%B3gicas%20espa%C3%B1olas%20(English%20ed.)&rft.au=K%C3%BC%C3%A7%C3%BCkarda,%20A.&rft.date=2022-06&rft.volume=46&rft.issue=5&rft.spage=301&rft.epage=309&rft.pages=301-309&rft.issn=2173-5786&rft.eissn=2173-5786&rft_id=info:doi/10.1016/j.acuroe.2021.12.005&rft_dat=%3Cproquest_cross%3E2637318186%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2074-8fc42a59cdc946f96f529840216b23a230fac70b3d1c1494c5b0586105eeae7a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2637318186&rft_id=info:pmid/35256324&rfr_iscdi=true |